(IKT) – PRNewswire
-
Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib
-
Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
-
Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib
-
Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro
-
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
-
Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023
-
Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements
-
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
-
Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study
-
Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease
-
Inhibikase Therapeutics to Present at the LD Micro Invitational XIII
-
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
-
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
-
Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
-
Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
-
Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease
-
Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase
-
Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity
-
Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023
-
Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders
-
Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023
-
Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro
-
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy
-
Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
-
Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules
-
Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules
-
Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders
-
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease
-
Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro
-
Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs
-
Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
-
Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
-
Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
-
Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs
-
Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference
-
Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference
-
Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress
-
Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
-
Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors
-
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia
-
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
-
Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
-
Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022
-
Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review
-
Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
-
Inhibikase Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
-
Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
-
Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
-
Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022
-
Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity
Back to IKT Stock Lookup
